Amit Agarwal

Amit Agarwal

Celgene Inc. - Summit / United States
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 4401778
-
person_outline Amit Agarwal's MOST POPULAR ARTICLES
1-) Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MMP Moreau, A Chanan-Khan, AW Roberts, AB Agarwal, T Facon, S Kumar, ...Blood, The Journal of the American Society of Hematology 130 (22), 2392-2400, 20172462017
2-) Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B-and T-cell non-Hodgkin lymphomasJW Friedberg, D Mahadevan, E Cebula, D Persky, I Lossos, AB Agarwal, ...Journal of clinical oncology 32 (1), 44, 20142262014
3-) Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and …A Agarwal, IM GhobrialClinical Cancer Research 19 (5), 985-994, 20131092013
4-) Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatmentDS Siegel, GJ Schiller, C Samaras, M Sebag, J Berdeja, S Ganguly, ...Leukemia 34 (12), 3286-3297, 2020832020
5-) KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myelomaS Jagannath, Y Lin, H Goldschmidt, D Reece, A Nooka, A Senin, ...Blood cancer journal 11 (6), 116, 2021732021